Aspirin + Alpha lipoic acid + Olmesartan + Placebo

Pre-clinicalCompleted

1 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Impaired Glucose Tolerance

Conditions

Impaired Glucose Tolerance, Prediabetic State

Trial Timeline

May 1, 2005 → May 1, 2011

NCT ID

NCT00122447

About Aspirin + Alpha lipoic acid + Olmesartan + Placebo

Aspirin + Alpha lipoic acid + Olmesartan + Placebo is a pre-clinical stage product being developed by Daiichi Sankyo for Impaired Glucose Tolerance. The current trial status is completed. This product is registered under clinical trial identifier NCT00122447. Target conditions include Impaired Glucose Tolerance, Prediabetic State.

What happened to similar drugs?

3 of 5 similar drugs in Impaired Glucose Tolerance were approved

Approved (3) Terminated (1) Active (2)

✅Exenatide + MetforminEli LillyApproved

✅Immediate switch to TDF/FTC/RPV + Switch to TDF/FTC/RPV after 24 weeksGilead SciencesApproved

✅Gabapentin + Gabapentin + Gabapentin + GabapentinPfizerApproved

🔄balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg + balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg + dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozinAstraZenecaPhase 3

🔄Ramipril + RosiglitazonePfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00122447	Pre-clinical	Completed	May 1, 2005	May 1, 2011	Impaired Glucose Tolerance

Competing Products

19 competing products in Impaired Glucose Tolerance

See all competitors

Product	Company	Stage	Hype Score
ASP8825	Astellas Pharma	Phase 1	29
ASP015K	Astellas Pharma	Phase 1	29
ASP015K	Astellas Pharma	Phase 1	29
Gilteritinib	Astellas Pharma	Phase 1	29
fospropofol + fospropofol + fospropofol + fospropofol	Eisai	Pre-clinical	18
Exenatide + Metformin	Eli Lilly	Approved	43
Apatinib Mesylate	Jiangsu Hengrui Medicine	Phase 1	25
balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg + balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg + dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin	AstraZeneca	Phase 3	47
Tetanus & Diphtheria booster vaccine (Td) + TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine] + Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)	Merck	Pre-clinical	26
ASA404	Novartis	Phase 1	21
MAS825 + Standard of Care (SoC)	Novartis	Phase 2	35
DFV890 + Standard of Care (SoC)	Novartis	Phase 2	35
Immediate switch to TDF/FTC/RPV + Switch to TDF/FTC/RPV after 24 weeks	Gilead Sciences	Approved	43
Gabapentin + Gabapentin + Gabapentin + Gabapentin	Pfizer	Approved	35
Ramipril + Rosiglitazone	Pfizer	Phase 3	40
HSK7653 10mg Q2W + HSK7653 25mg Q2W + Placebo	Haisco Pharmaceutical Group	Phase 2	35
NBI-98854 50 mg capsule	Neurocrine Biosciences	Phase 1	26
BIS-001ER	Supernus Pharmaceuticals	Phase 1/2	30
GFT505 80mg + Placebo	Genfit	Phase 2	25